Pretreatment Glasgow prognostic score as a biomarker of outcomes in nivolumab-treated patients with advanced gastric cancer

Nivolumab might provide overall survival
benefits for patients with advanced gastric cancer in Japan, South Korea, and
Taiwan. However, it is effective in only a limited number of patients. Glasgow
prognostic score is an indicator of systematic inflammatory response and
nutritional status. This study aimed to investigate the ability of the Glasgow
prognostic score and other markers to predict the prognosis in patients treated
with nivolumab.

We reviewed the medical records of all
patients with previously treated advanced gastric cancer who received nivolumab
between February 2015 and June 2019 at Hyogo Cancer Center. The patients were
categorized into two groups according to their Glasgow prognostic score. In
total, 53.3% and 46.7% of patients were assigned to groups with a Glasgow
prognostic score of 0, or that of 1 or 2, respectively.

The median progression-free survival and
median overall survival were 2.3 and 5.7 months among all participants. The
median progression-free survival (3.6 vs. 1.4 months; p = 0.015) and median
overall survival (16.4 vs. 4.2 months; p = 0.0006) were significantly longer in
patients with a Glasgow prognostic score of 0 than in those with a Glasgow
prognostic score of 1 or 2.

Pretreatment Glasgow prognostic score of 0
was associated with better outcomes. This study suggests that Glasgow
prognostic score may be a prognostic biomarker in patients with advanced
gastric cancer treated with nivolumab.